Your browser doesn't support javascript.
loading
Evaluation of the effect of D-002, a mixture of beeswax alcohols, on osteoarthritis symptoms.
Puente, Roberto; Illnait, José; Mas, Rosa; Carbajal, Daisy; Mendoza, Sarahí; Fernández, Julio César; Mesa, Meilis; Gámez, Rafael; Reyes, Pablo.
Afiliación
  • Puente R; Surgical Medical Research Centre, Havana, Cuba.
  • Illnait J; Surgical Medical Research Centre, Havana, Cuba.
  • Mas R; Centre of Natural Products, National Centre for Scientific Research, Havana, Cuba.
  • Carbajal D; Centre of Natural Products, National Centre for Scientific Research, Havana, Cuba.
  • Mendoza S; Centre of Natural Products, National Centre for Scientific Research, Havana, Cuba.
  • Fernández JC; Centre of Natural Products, National Centre for Scientific Research, Havana, Cuba.
  • Mesa M; Surgical Medical Research Centre, Havana, Cuba.
  • Gámez R; Centre of Natural Products, National Centre for Scientific Research, Havana, Cuba.
  • Reyes P; Software Group, National Centre for Scientific Research, Havana, Cuba.
Korean J Intern Med ; 29(2): 191-202, 2014 Mar.
Article en En | MEDLINE | ID: mdl-24648802
BACKGROUND/AIMS: Nonsteroidal anti-inflammatory drugs relieve osteoarthritis (OA) symptoms but cause adverse effects. D-002, a mixture of beeswax alcohols, is effective against experimental OA. A pilot study found that D-002 (50 mg/day) for 8 weeks improves OA symptoms. The aim of this study was to investigate the effects of D-002 (50 to 100 mg/day) administered for 6 weeks on OA symptoms. METHODS: Patients with OA symptoms were double-blindly randomized to D-002 (50 mg) or placebo for 6 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analog scale (VAS) scores. Patients without symptom improvement at week 3 were titrated to two daily tablets. The primary outcome was the total WOMAC score. WOMAC pain, joint stiffness and physical function scores, VAS score, and use of rescue medications were secondary outcomes. RESULTS: All randomized patients (n = 60) completed the study, and 23 experienced dose titration (two in the D-002 and 21 in the placebo groups). At study completion, D-002 reduced total WOMAC (65.4%), pain (54.9%), joint stiffness (76.8%), and physical function (66.9%) WOMAC scores, and the VAS score (46.8%) versus placebo. These reductions were significant beginning in the second week, and became enhanced during the trial. The use of rescue medication by the D-002 (6/30) group was lower than that in the placebo (17/30) group. The treatment was well tolerated. Seven patients (two in the D-002 and five in the placebo group) reported adverse events. CONCLUSIONS: These results indicate that D-002 (50 to 100 mg/day) for 6 weeks ameliorated arthritic symptoms and was well tolerated.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoartritis / Alcoholes Grasos / Antiinfecciosos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Caribe / Cuba Idioma: En Revista: Korean J Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2014 Tipo del documento: Article País de afiliación: Cuba Pais de publicación: Corea del Sur

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoartritis / Alcoholes Grasos / Antiinfecciosos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Caribe / Cuba Idioma: En Revista: Korean J Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2014 Tipo del documento: Article País de afiliación: Cuba Pais de publicación: Corea del Sur